Gallium-piridoxal isonicotinoyl hydrazone (Ga-PIH), a novel cytotoxic gallium complex. A comparative study with gallium nitrate

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1733-1737

  Knorr, Gregory M ^a   Chitambar, Christopher R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chelator; Chemotherapy; Gallium; Iron; Leukemic cell growth; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; GALLIUM NITRATE; GALLIUM PYRIDOXALISONICOTINYLHYDRAZONE; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; GALLIUM; GALLIUM PYRIDOXAL ISONICOTINOYL HYDRAZONE; GALLIUM-PYRIDOXAL ISONICOTINOYL HYDRAZONE; ORGANOMETALLIC COMPOUND;

ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRON TRANSPORT; ISOTOPE LABELING; LEUKEMIA CELL; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; CELL CULTURE; CELL DIVISION; CELL LINE; DRUG EFFECT; METABOLISM;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE; GALLIUM; HUMANS; IRON; ORGANOMETALLIC COMPOUNDS; TRANSFERRIN; TUMOR CELLS, CULTURED;

EID: 0031594953     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Keller J, Bartolucci A, Carpenter Jr.JT, and Feagler J: Phase II evaluation of bolus gallium nitrate in Iymphoproliferative disorders: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 1221-1223, 1986.
2. Weick JK, Stephens RL, Baker LH and Jones SE: Gallium nitrate in malignant Iymphoma: A Southwest Oncology Group study. Cancer Treat Rep 67: 823-825, 1983.
3. Warrell RPJr, Coonley CJ, Straus DJ and Young CW: Treatment of patients with advanced malignant Iymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51: 1982-1987, 1983.
4. Chitambar CR, Zahir SA, Ritch PS and Anderson T: Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's Iymphoma. Am J Clin Oncol 20: 173-178, 1997.
5. Crawford ED, Saiers JH, Baker LH, Costanzi JH and Bukowski RM: Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology 38: 355-357, 1991.
6. Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M and Bosl GJ: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tumors. Cancer 68: 2561-2565, 1991.
7. Chitambar CR and Seligrnan PA: Effects of different transferrin forms on transferrin receptor 10 expression, iron uptake and cellular proliferation of human leukemic HL60 cells: Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J Clin Invest 78: 1538-1546, 1986.
8. Chitambar CR, Matthaeus WG, Antholine WE, Graff K and O'Brien WJ: Inhibition of leukemic HL60 cell growth by transferrin-gallium: Effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea, Blood 72: 1930-1936, 1988.
9. Chitambar CR, Narasimhan J, Guy J, Sem DS and O'Brien WJ: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 51: 6199-6201, 1991.
10. 59Fe uptake by cultured mouse myeloma cells. Cancer Res 37: 3634-3638, 1977.
11. Harris WR and Pecoraro VL: Thermodynamic binding constants for gallium transferrin. Biochemistry 22: 292-299, 1983.
12. Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD and Williams DL: Common pathway for tumor cell uptake of Gallium-67 and Iron-59 via a transferrin receptor. J Natl Cancer Inst 64: 41-53, 1980.
13. Chitambar CR and Zivkovic Z: Uptake of gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res 47: 3929-3934, 1987.
14. Chitambar CR and Sax D: Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells. Blood 80: 505-511, 1992.
15. Richardson DR, Tran EH and Ponka P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295-4306, 1995.
16. Ponka P, Schulman HM and Wilczynska A: Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim Biophys Acta 718: 151-156, 1982.
17. Landschulz W, Thesleff I and Ekblom P: A lipophilic iron chelator can replace transferrin as a stimulator of cell proliferation and differentiation. J Cell Biol 98: 596-601, 1984.
18. Chitambar CR, Boon P and Wereley JP: Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. Clin Cancer Res 2: 1009-1015, 1996.
19. Chitambar CR and Wereley JP: Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. J Biol Chem 272: 12151-12157, 1997.
20. Bates GW and Schlabach MR: The reaction of ferric salts with transferrin. J Biol Chem 248: 3228-3232, 1973.
21. Hunter HM and Greenwood FC: Preparation of iodine-131 labelled human growth of high specific activity. Nature 194: 495-496, 1962.
22. Sah PPT: Nicotinyl and isonicotinyl hydrazones of pyridoxal. JA Chem Soc 76: 300, 1954.
23. Ponka, P., Borova, J., Neuwirt, J., and Fuchs, O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 97: 317-321, 1979.
24. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytoxiciry assays. J Immmunol Methods 65: 55-63, 1983.
25. Chitambar CR and Narasimhan J: Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 59: 3-10, 1991.
26. Hentze MW and Kuhn LC: Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 93: 8175-8182, 1996.
27. Brittenham GM: Disorders of iron metabolism: Iron deficiency and overload. In: R Huffman EJ Benz, Jr, SJ Shattil, B Furie and HJ Cohen (eds.), Hematology, Basic Principles and Practice, pp. 327-349, New York: Churchill Livingstone. 1991.